

*See E1  
31 Cont* wherein said cysteine residues are identified in SEQ ID NO:4.

**REMARKS**

Claim 4 has been amended to more clearly claim the invention and to correct the omission of a period. A VERSION WITH MARKINGS TO SHOW CHANGES MADE is attached in which deletions are shown within brackets and additions are underlined.

In the Notice from the Office, the Examiner objects to the omission of the reference to a SEQ ID NO: identifier in Claim 4. This reference has now been added.

**Conclusion**

In light of the Applicant's amendments to the claims, it is respectfully submitted that the present application is in condition for allowance. Should the Examiner have any remaining concerns which might prevent the prompt allowance of the application, the Examiner is respectfully invited to contact the undersigned at the telephone number appearing below.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 18 April 2001

By: Daniel Altman

Daniel E. Altman  
Registration No. 34,115  
Attorney of Record  
620 Newport Center Drive  
Sixteenth Floor  
Newport Beach, CA 92660  
(949) 760-0404

VERSION WITH MARKINGS TO SHOW CHANGES MADE

4. **(Amended Four Times)** The isolated polypeptide of Claim [3] 1, wherein said peptide has at least one pair of disulfide bonded cysteine residues selected from the group consisting of:

- (i) Cys<sub>71</sub> - Cys<sub>189</sub>; and
- (ii) Cys<sub>257</sub> - Cys<sub>270</sub>;
- (iii) Cys<sub>259</sub> - Cys<sub>270</sub>;
- (iv) Cys<sub>306</sub> - Cys<sub>322</sub>; and
- (v) Cys<sub>362</sub> - Cys<sub>365</sub>;

wherein said cysteine residues are identified in SEQ ID NO:4..